Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

BACKGROUND: Daclizumab high-yield process (DAC HYP), a humanized immunoglobulin G1 monoclonal antibody specific for the α subunit (CD25) of the high-affinity interleukin-2 receptor, has demonstrated efficacy for treatment of relapsing forms of multiple sclerosis in Phase II and III clinical trials....

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Jonathan Q, Othman, Ahmed A, Mikulskis, Alvydas, Wolstencroft, Paul, Elkins, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755689/
https://www.ncbi.nlm.nih.gov/pubmed/26929672
http://dx.doi.org/10.2147/CPAA.S98221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755689/
https://www.ncbi.nlm.nih.gov/pubmed/26929672
http://dx.doi.org/10.2147/CPAA.S98221

Ejemplares similares